Pain Therapeutics, Inc. (PTIE) Hit All-Time Low at $2.14

June 29, 2018 - By Julia Strobel

On Jun, 29, all time low was reached by Pain Therapeutics, Inc. (NASDAQ:PTIE). Today’s share price was $2.14. It’s 6.00 % below our $2.01. Barchart.com announced this technical setup. The company has $14.76M market cap. At $2.01 stock price target, the company valuation changes by $885,360 less.

Ticker’s shares touched $2.14 during the last trading session after 5.10% change.Pain Therapeutics, Inc. is uptrending after having risen 133.72% since June 29, 2017. PTIE has 274,326 volume or 132.03% up from normal. PTIE outperformed the S&P500 by 121.15%.

For more Pain Therapeutics, Inc. (NASDAQ:PTIE) news announced recently go to: Streetinsider.com, Nasdaq.com, Seekingalpha.com, Benzinga.com or Benzinga.com. The titles are as follows: “Pre-Open Movers 06/27: (DFBG) (CARA) (I) Higher; (AQXP) (PTIE) (DRRX) Lower (more…)” announced on June 27, 2018, “Pain Therapeutics Announces Results of FDA Advisory Committee Meeting for REMOXY ER” on June 26, 2018, “Key events next week – healthcare” with a publish date: June 21, 2018, “20 Stocks Moving In Thursday’s Pre-Market Session” and the last “23 Stocks Moving In Wednesday’s Pre-Market Session” with publication date: June 27, 2018.

Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States.The firm is valued at $14.76 million. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain.Currently it has negative earnings. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood diagnostic/biomarker to detect Alzheimer's disease.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: